Alkermes moves into profit as Elan delivers

Company brings fiscal year in line with calendar

Richard Pops, chief executive of Alkermes: “Our financial results reflect the financial transformation of Alkermes.” Photograph: Aidan Crawley
Richard Pops, chief executive of Alkermes: “Our financial results reflect the financial transformation of Alkermes.” Photograph: Aidan Crawley

Alkermes, the company that acquired Elan Drug Technologies, yesterday reported "robust" results for what it called a "remarkable year".

Increased revenues for manufacturing drugs for third parties along with stronger royalty income saw the company report a profit of $25 million, a turnaround from a $113.7 million loss the previous year. Revenues were 48 per cent stronger at $575.5 million.

The major driver of that growth was the Elan Drug Technologies acquisition in September 2011. The latest results reflect the first full-year contribution from that deal.

The company reported profit after tax of $3 million for the final quarter of the year, equivalent to two US cents a share, on revenues of $163.4 million. That compared with a loss of $63.4 million in the same period last year, or 49 cents a share. "Our financial results reflect the financial transformation of Alkermes," chief executive Richard Pops said.

“Our business is now evolving to the next stage as our pipeline of highly differentiated candidates advances and demonstrates its blockbuster potential.”

  • Join The Irish Times on WhatsApp and stay up to date

  • Sign up to the Business Today newsletter for the latest new and commentary in your inbox

  • Listen to Inside Business podcast for a look at business and economics from an Irish perspective

Dominic Coyle

Dominic Coyle

Dominic Coyle is Deputy Business Editor of The Irish Times